The use of oral radiographic contrast agents in the management of hyperthyroidism

Thyroid

Volumn 11, Issue 6, 2001, Pages 561-567

  Fontanilla, J C ^a   Schneider, A B ^a   Sarne, D H ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; BETAMETHASONE; IODINATED CONTRAST MEDIUM; IOPANOIC ACID; IOPODATE SODIUM; IOPODIC ACID; LEVOTHYROXINE; LIOTHYRONINE; POTASSIUM IODIDE; PROPRANOLOL; THYROXINE;

DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DYSURIA; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; LIOTHYRONINE BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; THYROID HORMONE RELEASE; THYROTOXICOSIS;

EID: 0034948688     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/105072501750302868     Document Type: Review

References (70)

1. Pathways of metabolism of thyroid hormones
2. Changes of circulating thyroxine, triiodothyronine and reverse triiodothyronine after radiographic contrast agents
3. Changes in circulating iodothyronines in euthyroid and hyperthyroid subjects given ipodate (Oragrafin), an agent for oral cholecystography
4. The use of X-ray contrast media in the treatment of hyperthyroidism
5. Long term treatment of Graves' disease with iopanoic acid (Telepaque)
6. Sodium ipodate and methimazole in the long-term treatment of hyperthyroid Graves' disease
7. Sodium ipodate in the treatment of toxic diffuse goiter. Short-term and long-term effects on thyrotoxicosis
8. Iopanoic acid is of minimal benefit in the treatment of severe hyperthyroidism: Conclusions from a case study
9. Prolonged treatment of hyperthyroidism with sodium tyropanoate, an oral cholecystographic agent: A reevaluation of its clinical utility
10. Comparison sodium ipodate (oragrafin) and propylthiouracil in early treatment of hyperthyroidism
11. The effect of repeated administration of ipodate (Oragrafin) in hyperthyroidism
12. Use of sodium ipodate in management of hyperthyroidism in subacute thyroiditis
13. The therapeutic efficacy of oral cholecystographic agent (ipoanoic acid) in the management of hyperthyroidism
14. The effects of iopodate on the serum iodothyronine pattern in normal subjects
15. Thyroid, renal, and hepatic function tests following cholecystography with high-dose contrast agents
16. Effects of three-day oral cholecystography on serum iodothyronines and TSH concentrations: Comparison of the effects among some cholecystographic agents and the effects of iopanoic acid on the pituitary-thyroid axis
17. Dual mechanisms of regulation of type I iodothyronine 5′-deiodinase in the rat kidney, liver, and thyroid gland. Implications for the treatment of hyperthyroidism with radiographic contrast agents
18. Evidence for two tissue-specific pathways for in vivo thyroxine 5′-deiodination in the rat
19. Inhibition of intrapituitary thyroxine to 3.5.3′-triiodothyronine conversion prevents the acute suppression of thyrotropin release by thyroxine in hypothyroid rats
20. Iodothyronine metabolism in liver and kidney homogenates from hyperthyroid and hypothyroid rats
21. Iodothyronine metabolism in rat liver homogenates
22. Ipodate restores the fasting-induced decrement In thyrotropin secretion
23. Increased plasma concentrations of thyrotropin in healthy subjects during three weeks peroral administration of a small dose of ipodate
24. The effect of iopanoic acid on the regulation of thyrotropin secretion in euthyroid subjects
25. Effects of sodium ipodate and propylthiouracil in athyreotic human subjects, role of triiodothyronine and pituitary thyroxine monodeiodination in thyrotrophin regulation
26. Effect of Iopanoic acid on the pituitary-thyroid axis: Time sequence of changes in serum iodothyronines, thyrotropin, and prolactin concentrations and responses to thyroid hormones
27. Effects of the combination of dexamethasone and sodium ipodate on serum thyroid hormones in Graves' disease
28. Effect of sodium ipodate and iodide on free T4 and free T3 concentrations in patients with Graves' disease
29. Comparative effects of sodium ipodate and iodide on serum thyroid hormone concentrations in patients with Graves' disease
30. Treatment of hyperthyroidism with sodium ipodate (oragrafin) in addition to propylthiouracil and propranolol
31. Long term treatment of Graves' hyperthyroidism with sodium ipodate
32. Ipodate therapy in patients with severe destruction-induced thyrotoxicosis
33. Thyroid hormones in serum: Effects of x-ray contrast media
34. Effects of amiodarone on thyroid function
35. Multisite inhibition by ipodate of iodothyronine secretion from perfused dog thyroid lobes
36. The effect of some iodine-containing radiocontrast agents on iodothyronine secretion from the perfused canine thyroid
37. Inhibitory effect of various radiographic contrast agents on secretion of thyroxine by the dog thyroid and on peripheral and thyroidal deiodination of thyroxine to tri-iodothyronine
38. Inhibition by iodine of the release of thyroxine from the thyroid glands of patients with thyrotoxicosis
39. Inhibition of hepatic binding of thyroxine by cholecystographic agents
40. Effects of cholecystographic agents and sulfobromophthalein on binding of thyroid hormones to serum proteins
41. Effect of simultaneously administered iopanoic acid and thyrotropin releasing hormone (TRH) on thyroid hormone metabolism in euthyroid subjects
42. Cardiac catheterization dye does not affect serum thyroid hormone concentrations or TSH secretion
43. Iodothyronine and thyrotropin concentrations after iodoamide administration for angiographic studies
44. Hepatic excretion of cholecystopaques introduced into the canine jejunum
45. Roentgenographic contrast agents inhibit triiodothyronine binding to nuclear receptors in vitro
46. The effects of radiographic contrast agents and other compounds on the nuclear binding of L-[125I]triiodothyronine in dispersed human skin fibroblasts
47. Ipodate and 8-anilino-1-naphthalene sulfonic acid block receptor binding of T3 in rat liver
48. A study of cardiac effects of thyroid hormones: Evidence for amelioration of the effects of thyroxine by sodium ipodate
49. Acute L-thyroxine overdose; therapy with sodium ipodate: Evaluation of clinical and physiologic parameters
50. Successful treatment of massive acute thyroid hormone poisoning with iopanoic acid
51. Further studies on the long-term treatment of Graves' hyperthyroidism with ipodate: Assessment of a minimal effective dose
52. Treatment of neonatal Graves' disease with sodium ipodate. A case report
53. Treatment of neonatal hyperthyroidism due to Graves' disease with sodium ipodate
54. Management of neonatal Graves disease with iopanoic acid
55. Rapid preoperative preparation in hyperthyroidism
56. Sodium ipodate in the preparation of Graves' hyperthyroid patients for thyroidectomy
57. Sodium ipodate (oragrafin) in the preoperative preparation of Graves' hyperthyroidism
58. Therapy of Graves' disease with sodium ipodate is associated with a high recurrence rate of hyperthyroidism
59. Comparison of methimazole, methimazole and sodium ipodate, and methimazole and saturated solution of potassium iodide in the early treatment of hyperthyroid Graves' disease
60. Iopanoic acid as an adjunct to carbimazole in the management of hyperthyroidism
61. Hyperthyroidism after cholecystography
62. Resistant hyperthyroidism induced by sodium iopodate used as treatment for Graves' disease
63. Iodine content of human tissues after administration of iodine containing drugs or contrast media
64. Oral cholecystography with iopanoic acid
65. Fractionated dose cholecystography: A comparison between iopanoic acid and sodium ipodate
66. Acute thrombocytopenia following oral cholecystography with iopanoic acid
67. Thrombocytopenic purpura following iopanoic acid ingestion
68. Coexistence of struma ovarii and Graves' disease
69. Iopanoic acid-induced decrease of circulating T3 causes a significant increase in GH responsiveness to GH releasing hormone in thyrotoxic patients
70. Thyrotoxicosis factitia in a post-aortocoronary bypass patient